MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Начало・Списък с акции・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Затворен

СекторЗдравеопазване

57.76 -3.05

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

57.75

Максимум

60.69

Ключови измерители
By Trading Economics
Приходи	-1.1B 76M
Продажби	442M 12B
P/E Средно за сектора	14.05 63.778
EPS	1.67
Дивидентна доходност	4.07
Марж на печалбата	0.616
Служители	34,100
EBITDA	-1.9B 2.6B

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+2.23% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	4.07% 2.39%
Следващи печалби	24.04.2025 г.
Следваща дата на дивидент	1.05.2025 г.
Следваща дата на екс-дивидент	4.04.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	311M 121B
Предишно отваряне	60.81
Предишно затваряне	57.76

Настроения в новините

By Acuity

37%

63%

130 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

59.46 / 61.05 Подкрепа & съпротива

Bristol-Myers Squibb Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.03.2025 г., 10:13 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11.03.2025 г., 10:13 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

6.02.2025 г., 12:13 ч. UTC

Печалби

Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook

14.03.2025 г., 09:30 ч. UTC

Топ новини

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

11.03.2025 г., 02:26 ч. UTC

Придобивния, сливания и поглъщания

Abecma Is an Immunotherapy Indicated for Treatment of Relapsed or Refractory Multiple Myeloma >TSVT

11.03.2025 г., 02:26 ч. UTC

Придобивния, сливания и поглъщания

Stockholders Owning About 5.3% of 2seventy Bio Shares Have Agreed to Tender All Their Shares >TSVT

11.03.2025 г., 02:26 ч. UTC

Придобивния, сливания и поглъщания

2seventy Bio CEO: Rationale for Deal Clear, in Line With Focus on Unlocking Value of Abecma >TSVT

11.03.2025 г., 02:23 ч. UTC

Придобивния, сливания и поглъщания

2seventy Bio Stock Will No Longer Trade on Nasdaq After Closing of Deal, Expected in 2Q >TSVT

11.03.2025 г., 02:22 ч. UTC

Придобивния, сливания и поглъщания

2seventy Bio's Board Unanimously Recommends Stockholders Tender Shares in Offer >TSVT

11.03.2025 г., 02:21 ч. UTC

Придобивния, сливания и поглъщания

Bristol Myers Deal Represents 88% Premium to 2seventy Closing Price of $2.66 on March 7 >TSVT

11.03.2025 г., 02:21 ч. UTC

Придобивния, сливания и поглъщания

Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT

11.03.2025 г., 02:19 ч. UTC

Придобивния, сливания и поглъщания

2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6.02.2025 г., 15:35 ч. UTC

Печалби

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD

6.02.2025 г., 13:56 ч. UTC

Печалби

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD

6.02.2025 г., 13:25 ч. UTC

Топ новини

Печалби

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6.02.2025 г., 12:00 ч. UTC

Печалби

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol-Myers Squibb 4Q Gross Margin 61.0% >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol-Myers Squibb 4Q Rev $12.3B >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol-Myers Squibb 4Q Net $72M >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol-Myers Squibb 4Q EPS 4c >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol Myers Squibb: Expanding Existing Strategic Productivity Initiative to Include About $2B in Additional Annualized Cost Savings by the End of 2027 >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol Myers Squibb: 4Q Growth Portfolio Revenue Primarily Due to Higher Demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol Myers Squibb 4Q Rev $12.34B >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY

6.02.2025 г., 11:59 ч. UTC

Печалби

Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY

Сравнение с други в отрасъла

Ценова промяна

Bristol-Myers Squibb Co. Прогноза

Ценова цел

By TipRanks

2.23% нагоре

12-месечна прогноза

Среден 60.93 USD 2.23%

Висок 70 USD

Нисък 37 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за Bristol-Myers Squibb Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

16 ratings

Купи

Задържане

Продай

Според 16 анализатори, дали борсови рейтинги на Bristol-Myers Squibb Co. през последните 3 месеца.

Техническа оценка

By Trading Central

59.46 / 61.05Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Bearish events outweigh bullish events.

Настроение

By Acuity

130 / 386 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.